GT Biopharma (GTBP)
Developer of natural-killer-cell engagers for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Develops TriKE fusion proteins that activate natural killer cells against cancer targets, with a preclinical autoimmune program. The asset-light business has no approved products or revenue and depends on University of Minnesota licenses, external development partners, and additional funding.
Develops TriKE and Dual Targeting TriKE fusion proteins that connect natural killer cells to cancer-cell antigens while supplying an IL-15 signal. The active pipeline includes GTB-3650 for acute myeloid leukemia and high-risk myelodysplastic syndrome, GTB-5550 for advanced solid tumors, and GTB-7550, a preclinical CD19 program for lupus and other autoimmune disorders.
Operates as a virtual, asset-light biopharmaceutical business with worldwide licensed rights from the University of Minnesota and clinical execution centered in the United States. No approved products or product revenue support the business; development relies on the university, consultants, research institutions, contract manufacturers, and external funding.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.0M · Total debt $0 · Total assets $5.8M · Shareholders' equity $3.6M
- Revenue
- $0
- Operating income
- −$4.5M
- Net income
- −$4.5M
No dividends on record.
| Institutions58 holders · as of Jun 30, 2026 | 4.70% | 2.12M shares | |
| Insiders1 holder · as of Feb 5, 2019 | 0.02% | 9.2K shares | |
| Strategic holders2 holders · as of Dec 4, 2017 | 0.02% | 7.3K shares | |
| Otherremainder | 95.26% | 42.97M shares |
45.11M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (45.11M in the company's Sep 3, 2026 report, 31.55M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 0.83% | 376,399 | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.59% | 266,788 | 13Fas of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.50% | 225,938 | 13Fas of Jun 30, 2026 |
HRT Financial LPInstitution | 0.24% | 107,140 | 13Fas of Jun 30, 2026 |
Everhart Financial Group, Inc.Institution | 0.22% | 100,000 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Innate Pharma (ADR)
Closest NK-cell-engager platform across myeloid and B7-H3 programs.
- Pfizer
Approved CD33 therapy sets a direct AML treatment benchmark.
- Merck
Global co-developer of a leading B7-H3 solid-tumor ADC.
- Cabaletta Bio
Clinical CD19 CAR-T program pursues deep B-cell depletion in lupus.
- Kyverna Therapeutics
Later-stage CD19 CAR-T program targets B-cell-driven autoimmunity.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GT Biopharma | $0.2833 | −1.94% | $8.9M | — | — | — | — |
| Innate Pharma (ADR) | $2.17 | +2.36% | $203.8M | — | — | 60.6 | +1,574.1% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Cabaletta Bio | $3.58 | +0.14% | $582.1M | — | — | — | — |
| Kyverna Therapeutics | $8.62 | +3.17% | $523.8M | — | — | — | — |
| Median | 79.8 | 14.0 | 5.6 | +5.1% |